Foundayo (Orforglipron): The First GLP-1 Pill With No Food or Water Rules

The FDA approved Foundayo (orforglipron) on April 1, 2026, and it reached US pharmacies eight days later. It is the second GLP-1 available as a pill — but it is the first one that is not a peptide, and that single chemical fact explains almost everything that makes it different.

Semaglutide is a large peptide. Peptides are destroyed by digestion, which is why the Wegovy tablet has to be swallowed on an empty stomach with no more than four ounces of water, followed by a 30-minute fast. Orforglipron is a small molecule. It survives the gut on its own, so it comes with no food rules, no water limit, and no timing window.

How it compares to the other oral option

How much weight did people lose?

ATTAIN-1 enrolled 3,127 adults with obesity and without diabetes and ran 72 weeks. At the highest dose, mean weight change was −12.4% against −0.9% on placebo. Among those on the highest dose, 55% lost at least 10% of their body weight, 36% lost at least 15%, and 19% lost at least 20% — versus 13%, 6% and 3% on placebo.

One honest caveat that most coverage drops. That 12.4% is the efficacy estimand, which models what happens if people stay on treatment as directed. The treatment-regimen estimand, which counts everyone including those who stopped, came in at −11.2% versus −2.1% for placebo. Both are legitimate; they answer different questions. Compare like with like when you see numbers for other drugs.

Put beside the other options, orforglipron is the least potent of the three. The Wegovy tablet reported 16.6% among adherent participants and the injection 14.9% in STEP 1. These come from separate trials and are not head-to-head, but the ordering is consistent enough to be worth knowing. You are trading some efficacy for convenience and, at the lower doses, for price.

ATTAIN-2 tested it in 1,613 adults who had obesity and type 2 diabetes: 10.5% weight reduction at the highest dose versus 2.2% on placebo, with A1C down 1.8%.

The titration is slower than people expect

Foundayo starts at 0.8 mg once daily and moves up no sooner than every 30 days: 0.8, then 2.5, then 5.5 mg. From there your prescriber may go to 9, 14.5 or 17.2 mg depending on response and tolerability. The maximum is 17.2 mg once daily.

That means roughly five months before anyone reaches the top dose — longer than the Wegovy tablet's 91 days. Patience is built into the label, and the reason is the same as with every drug in this class: going up faster buys you more nausea.

Taking it is genuinely simple. Once a day, with or without food, swallowed whole, never more than one tablet. If you miss a dose, take it as soon as you can and do not double up. If you miss seven or more consecutive doses, the label says to restart escalation at a lower dose rather than resuming where you left off.

The drug interactions that peptide GLP-1s don't have

This is the most consequential thing on the label and it is almost absent from consumer coverage. Because orforglipron is a small molecule, it is processed by the liver enzyme CYP3A4 — the same pathway that handles a long list of common drugs. Semaglutide and tirzepatide, being peptides, largely bypass this.

• Strong CYP3A4 inhibitors cap your Foundayo dose at 9 mg once daily — you cannot go to the top dose while taking one.
• Strong CYP3A4 inhibitors that also inhibit OATP1B should be avoided altogether. The label names ritonavir as the example.
• Strong CYP3A4 inducers should be avoided; with moderate inducers, effectiveness should be monitored and the dose adjusted as needed.
• Severe hepatic impairment (Child-Pugh C): not recommended. Mild and moderate need no adjustment, and neither does kidney impairment.

Common drugs in those categories include certain antifungals, some antibiotics, several HIV medications, and a few seizure medicines — plus St John's wort, which is a strong inducer and is sold without a prescription. Bring your full medication and supplement list to the appointment, not just the prescriptions.

What it is approved for — and what it is not

Foundayo is approved for weight reduction in adults with obesity, or with overweight plus at least one weight-related condition, alongside reduced calories and more activity.

That is the whole list. Unlike both forms of Wegovy, Foundayo is not approved to reduce cardiovascular risk. If you are taking a GLP-1 partly for your heart, that distinction matters, and it is the clearest reason someone might choose semaglutide over this despite the easier routine. The label also says it is not recommended alongside another GLP-1 receptor agonist.

The boxed warning says something unusual

Foundayo carries the same boxed warning as the rest of the class for thyroid C-cell tumours, and the same contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Read the actual wording, though, because it is not the same warning.

For semaglutide, the label states that the drug caused thyroid C-cell tumours in rodents. For orforglipron, the label states that the drug is not pharmacologically active in rats or mice and did not produce tumours in rodents — while noting the human relevance is undetermined.

That is a real difference in the underlying evidence rather than a wording change. It is not a clean bill of health: because the drug does not act on the receptor in those species, the standard rodent study could not have detected the effect in the first place, which is precisely why the warning stays. But if you have read that GLP-1s cause thyroid tumours in animals, this one did not, and that is worth knowing accurately.

Side effects

Gastrointestinal, as with the whole class, and mostly during dose escalation.

Hair loss appears on this label at 5% against 2% on placebo — in the same range reported for semaglutide, and for the same underlying reason. We cover why in GLP-1s and hair loss.

In ATTAIN-1, discontinuation due to adverse events ran from 5.1% at the lowest dose to 10.3% at the highest, against 2.6% on placebo. The trial reported no hepatic safety signal, which had been a live question for this drug class in development.

What it costs

Lilly launched it at $149 a month self-pay for the lowest dose through LillyDirect, with higher doses priced above that. Eligible commercially insured patients may pay as little as $25 a month with the savings card, and eligible Medicare Part D beneficiaries about $50 a month from July 1, 2026.

That entry price is the genuinely disruptive part. A branded, FDA-approved oral GLP-1 starting at $149 lands in territory that until recently belonged to compounded telehealth. Prices move, so confirm the current figure before deciding — our GLP-1 Cost Index tracks what each route costs at maintenance, which is the number that matters once you are past the starting dose.

Who is it actually for?

• A good fit if needles are a real barrier, if the Wegovy tablet's empty-stomach window does not survive contact with your mornings, if you travel often, or if the low-dose self-pay price is what makes treatment possible at all.
• Think harder if you want cardiovascular risk reduction on the label, if you are chasing maximum weight loss, if you take medicines that run through CYP3A4, or if you have severe liver impairment.